A carregar...
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
BACKGROUND: The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating dasatinib, which could expand under selective pressures during treatment. However,...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3409074/ https://ncbi.nlm.nih.gov/pubmed/22587422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-23 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|